Key oral presentation highlights the company’s prototype microfluidic chips for multi-omics workflows
908 Devices Inc (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, is showcasing its ZipChip CE-MS device for rapid characterization of critical product quality attributes for biologics, oligonucleotides, RNAs, and AAVs, with an oral presentation, seminar and 17 posters at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, June 4-8 in Houston. The majority of the scientific presentations are results from collaborators and key opinion leaders such as Weizmann Institute of Science, Dyne Therapeutics, Regeneron Pharmaceuticals, CPI, University of Wisconsin-Madison, and University of Connecticut.
Join the Revolution
908 Devices is revolutionizing chemical and biochemical analysis with its mass spec devices that are simple to operate, provide answers in minutes and are used at the point of need. The company’s ZipChip device leverages microchip-based Capillary Electrophoresis (CE) and nano-electrospray ionization technology to minimize sample prep burden, perform high-speed and high-resolution separations, and directly introduce samples into a Thermo Fisher Scientific, Bruker or Sciex mass spectrometer.
A key highlight of the company’s presence at the ASMS conference is its breakfast seminar on Protein Characterization of Biologics using Microchip CE-MS: From mAbs to AAVs, on Monday, June 5 at 7 am CT. Dr. Jonathan Bones and Dr. Josh Smith from the National Institute of Bioprocessing Research and Training (NIBRT) in Ireland share application highlights of using ZipChip for characterizations on proteins and adeno-associated virus (AAV). Dr. Bones will highlight his lab’s use of ZipChip for multi-characterization of proteins in applications including charge variant analysis, peptide mapping, and released glycan analysis of therapeutic proteins. He will also discuss ZipChip’s key advantages such as versatility, high sensitivity, short analysis times and lack of method development. Dr. Smith will highlight the successful use of ZipChip for rapid analysis of various serotypes of the AAVs. The detailed collaboration results are presented in three separate posters at this ASMS.
In a key oral presentation, Dr. Will Thompson from 908 Devices will present his collaboration with Professor Marc Foster from Duke University on Unifying the Multi-Omics World with Microchip Capillary Electrophoresis: Discovering Secrets in Six Dimensions from One Drop of Dried Blood. In this work, Dr. Thompson will describe a workflow using the company’s prototype microfluidic chips for its ZipChip capillary electrophoresis device coupled to a mass spec instrument, which allows independent metabolomic, peptidomic, top-down and bottom-up proteomics from a single sample containing 20 uL of dried blood.
In addition, 908 Devices will present another two posters on quantitation of amino acids in cell culture media using its REBEL desktop CE-MS device, a first-of-its-kind fresh and spent media analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line.
Exhibit and Presentations at ASMS
908 Devices will exhibit its handheld and desktop devices in booth #603 at ASMS. To see a complete list of posters the company is presenting with its collaborators and to register for the breakfast seminar, visit www.908devices.com/asms.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Source: 908 Devices Inc